Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

FDG-PET abnormalities leading to the diagnosis of an unusual case of probable neurosarcoidosis.

Wang Y, Andrews J, Jenkins Colon P, Wundes A.

Neurol Neuroimmunol Neuroinflamm. 2018 Sep 26;5(6):e506. doi: 10.1212/NXI.0000000000000506. eCollection 2018 Nov. No abstract available.

PMID:
30345332
2.

Lifetime exposure to ultraviolet radiation and the risk of multiple sclerosis in the US radiologic technologists cohort study.

Gallagher LG, Ilango S, Wundes A, Stobbe GA, Turk KW, Franklin GM, Linet MS, Freedman DM, Alexander BH, Checkoway H.

Mult Scler. 2018 Jun 1:1352458518783343. doi: 10.1177/1352458518783343. [Epub ahead of print]

PMID:
29932357
3.

Improving the quality of depression and pain care in multiple sclerosis using collaborative care: The MS-care trial protocol.

Ehde DM, Alschuler KN, Sullivan MD, Molton IP, Ciol MA, Bombardier CH, Curran MC, Gertz KJ, Wundes A, Fann JR.

Contemp Clin Trials. 2018 Jan;64:219-229. doi: 10.1016/j.cct.2017.10.001. Epub 2017 Oct 5.

PMID:
28987615
4.

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.

Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Steinmiller KC, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stuve O, Arnold DL, Wener MH, Georges GE, Wundes A, Kraft GH, Bowen JD.

Neurology. 2017 Feb 28;88(9):842-852. doi: 10.1212/WNL.0000000000003660. Epub 2017 Feb 1.

5.

Brain pathology of a patient 7years after autologous hematopoietic stem cell transplantation for multiple sclerosis.

Wundes A, Bowen JD, Kraft GH, Maravilla KR, McLaughlin B, von Geldern G, Georges G, Nash RA, Lu JQ.

J Neurol Sci. 2017 Feb 15;373:339-341. doi: 10.1016/j.jns.2017.01.016. Epub 2017 Jan 7.

PMID:
28131217
6.

Natalizumab-related PML 2 weeks after negative anti-JCV antibody assay.

Ontaneda D, Fox RJ, Gagne Brosseau MS, Stobbe G, Wundes A.

Neurology. 2016 Aug 30;87(9):957-8. doi: 10.1212/WNL.0000000000003081. No abstract available.

PMID:
27572430
7.

Accelerating international MS care through videoconference-based education and case consultation.

Alschuler KN, Wundes A, Dietrich DW, Boskovski B, Kuzmanovski I, Alexander KS, von Geldern G, Stobbe GA.

Neurology. 2016 Jul 5;87(1):e8-e10. doi: 10.1212/WNL.0000000000002812. No abstract available.

8.

Natalizumab-related PML 2 weeks after negative anti-JCV antibody assay.

Gagne Brosseau MS, Stobbe G, Wundes A.

Neurology. 2016 Feb 2;86(5):484-6. doi: 10.1212/WNL.0000000000002330. Epub 2016 Jan 6. No abstract available.

PMID:
26740679
9.

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.

Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stüve O, Arnold DL, Spychala ME, McConville KC, Harris KM, Phippard D, Georges GE, Wundes A, Kraft GH, Bowen JD.

JAMA Neurol. 2015 Feb;72(2):159-69. doi: 10.1001/jamaneurol.2014.3780.

10.

What do healthcare providers advise women with multiple sclerosis regarding pregnancy?

Wundes A, Pebdani RN, Amtmann D.

Mult Scler Int. 2014;2014:819216. doi: 10.1155/2014/819216. Epub 2014 Mar 5.

11.

Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results.

Bowen JD, Kraft GH, Wundes A, Guan Q, Maravilla KR, Gooley TA, McSweeney PA, Pavletic SZ, Openshaw H, Storb R, Wener M, McLaughlin BA, Henstorf GR, Nash RA.

Bone Marrow Transplant. 2012 Jul;47(7):946-51. doi: 10.1038/bmt.2011.208. Epub 2011 Nov 7.

12.

Contribution of intangible costs to the economic burden of multiple sclerosis.

Wundes A, Brown T, Bienen EJ, Coleman CI.

J Med Econ. 2010;13(4):626-32. doi: 10.3111/13696998.2010.525989. Epub 2010 Oct 18. Review.

PMID:
20950249
13.

Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.

Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.

Clin Neurol Neurosurg. 2010 Dec;112(10):876-82. doi: 10.1016/j.clineuro.2010.07.018. Epub 2010 Aug 19.

PMID:
20727669
14.

Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab.

Bonig H, Wundes A, Chang KH, Lucas S, Papayannopoulou T.

Blood. 2008 Apr 1;111(7):3439-41. doi: 10.1182/blood-2007-09-112052. Epub 2008 Jan 14.

15.

In vivo cytokine responses to interleukin-2 immunotherapy after autologous stem cell transplantation in children with solid tumors.

Bönig H, Laws HJ, Wundes A, Verheyen J, Hannen M, Kim YM, Banning U, Nürnberger W, Körholz D.

Bone Marrow Transplant. 2000 Jul;26(1):91-6.

Supplemental Content

Loading ...
Support Center